Dr Graeme Stasiuk G.Stasiuk@hull.ac.uk
Senior Lecturer in Molecular Imaging
ThrombiGlow: ‘Smart’ Multimodal Platelet Specific ‘Theranostic’ Drug Delivery Imaging
People Involved
Dr Simon Calaminus S.Calaminus@hull.ac.uk
Project Description
Cardiovascular diseases (CVD) including heart attacks and strokes constitute the leading cause of mortality in the UK. The pathology underlying CVD is called atherothrombosis and is a complex, multi-cellular-inflammatory disorder. Central to this is the uncontrolled activation of platelets, as exemplified by the clinical success of
anti-platelet drugs. While current therapy has been successful in reducing the burden of disease, arterial thrombosis continues to induce significant mortality leading to the desire for efficous therapeutic interventions. The aim of this studentship is to create a
series of state-of-the-art-therapeutic-imaging or ‘theranostic’ agents for advancing targeted and personalised therapy in platelet control. A platelet specific delivery systems based on nanoparticles for both drug-delivery and multimodal imaging will be developed. A range of in-vitro techniques will be used to validate specific platformplatelet
binding and efficacy of the drug-delivery system. The ability to monitor the localisation of a drug in the body and control its distribution has huge potential in increasing drug efficacy and improving anti-platelet therapy, alongside imaging thrombus formation in real-time.
| Type of Project | Project |
|---|---|
| Status | Project Complete |
| Funder(s) | British Heart Foundation |
| Value | £107,146.00 |
| Project Dates | Feb 1, 2017 - Jan 31, 2020 |
| Partner Organisations | No Partners |
You might also like
Development of Heavy Metal Free Quantum dot Lanthanide Conjugates for Sensing Aug 16, 2016 - Dec 31, 2018
The overall aim of this project to use innovative inorganic chemistry for the supramolecular self-assembly of novel heavy metal free nanocrystal (quantum dots) and lanthanide complexes to give multimodal contrast agents for molecular imaging. Key goa...
Read More about Development of Heavy Metal Free Quantum dot Lanthanide Conjugates for Sensing.
Development Of A Multimodal Bioimaging Platform For Detecting The Switch To Aggressive Prostate Cancer Oct 1, 2015 - Dec 31, 2018
Platelet cAMP signalling controls thrombosis through enhanced embolisation Oct 1, 2015 - Sep 30, 2018
The activation of protein kinase A (PKA) by prostacyclin inhibits platelet activation and therefore modulates arterial thrombosis. However, the role of PKA in controlling the stability of pre-existing thrombi is unclear. The stability of thrombi is r...
Read More about Platelet cAMP signalling controls thrombosis through enhanced embolisation.
Is zinc a critical modulator of cyclic nucleotide signalling? Oct 1, 2019 - Dec 31, 2022
inc (Zn2+) deficiency is present in multiple conditions from obesity to cancer. However importantly Zn2+ deficiency can lead to a bleeding phenotype.In this proposal we investigate how Zn2+ is important for the control of platelet cyclic nucleotide...
Read More about Is zinc a critical modulator of cyclic nucleotide signalling?.
TARGETING THE MYOSIN LIGHT CHAIN PHOSPHATASE WITH PEPTIDE DISRUPTORS: A NOVEL ANTIPLATELET THERAPEUTIC APPROACH Jul 3, 2023 - Jul 2, 2026
Platelet activation and thrombus formation play key roles in the pathogenesis of ischaemic cardiovascular diseases, one of the major causes of death in the UK. Many antiplatelet agents have been developed to manage these conditions; however, they are...
Read More about TARGETING THE MYOSIN LIGHT CHAIN PHOSPHATASE WITH PEPTIDE DISRUPTORS: A NOVEL ANTIPLATELET THERAPEUTIC APPROACH.